Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ali Sajadi

Urology Arlington, VA Medical Doctor

NPI 1326028614 CMS profile 150367

2200 Wilson Blvd Ste 102-18, Arlington, VA 22201

Open in the dashboard

General payments

$4,523

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ali Sajadi of Arlington, VA is reported in the CMS Open Payments database as having received $4,523 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $507 3
2024 General $47 2
2023 General $275 12
2022 General $1,031 53
2021 General $1,137 51
2020 General $647 32
2019 General $878 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Sajadi
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Ali Sajadi were reported at $507. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Ali Sajadi Urology median Middle half National median
2019 $878 $480 $147–$1,201 $163
2020 $647 $246 $87–$645 $114
2021 $1,137 $358 $111–$1,000 $132
2022 $1,031 $476 $143–$1,263 $149
2023 $275 $560 $168–$1,461 $160
2024 $47 $563 $170–$1,464 $164
2025 $507 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $725 25 payments
  2. Janssen Biotech, Inc. $581 24 payments
  3. Myriad Genetic Laboratories, Inc. $314 13 payments
  4. Urovant Sciences Inc $246 19 payments
  5. Antares Pharma, Inc. $244 12 payments
  6. Zimvie Inc. $217 5 payments
  7. Geistlich Pharma, North America, Inc. $209 1 payment
  8. Allergan Inc. $184 9 payments
  9. AxoGen $156 1 payment
  10. Coloplast Corp $143 6 payments
  11. Other $1,504 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,098 187 payments
  2. Education $425 8 payments
Products named General payments · program years 2019–2025
  1. ERLEADA $601 26 payments
  2. GEMTESA $299 21 payments
  3. MYRBETRIQ $224 15 payments
  4. XTANDI $221 12 payments
  5. Biomaterials $209 1 payment
  6. TSX Implants $203 4 payments
  7. BOTOX $197 10 payments
  8. BRAC CDx $149 3 payments
  9. Prolaris $110 7 payments
  10. ELIGARD $87 4 payments
  11. Other $2,306 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$11,002

Medicare's payments for the services billed

Medicare patients

65

Average age 76

Services billed

131

23 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 57%
Arthritis 55%
Diabetes 51%
Ischemic heart disease 46%
Atrial fibrillation 37%
Depression 37%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record